OCUGEN INC (OCGN)
Health Care · Gene therapy / inherited retinal disease treatment · NASDAQ
A gene therapy company developing novel modifier gene therapies to treat inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
What OCUGEN INC does
Ocugen is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and blindness. The company's core platform is a novel modifier gene therapy approach using nuclear hormone receptors (NHRs) to address genetic blindness diseases with a gene-agnostic strategy. Its lead programs include OCU400 for retinitis pigmentosa (RP), OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, with multiple late-stage trials underway and BLA submissions planned through 2027.
Themes: Gene therapy / inherited retinal diseases, Retinitis pigmentosa (RP) treatment, Stargardt disease / ABCA4-associated retinopathies, Geographic atrophy / age-related macular degeneration (AMD), Rare genetic blindness diseases, Advanced Therapy Medicinal Product (ATMP)
Fundamentals
- Price$1.39 as of 2026-08-21 close
- Market cap$471M as of 2026-08-21
- 1-year return+37.6% 2025-08-21 close $1.01 → 2026-08-21 close $1.39
- P/En/a negative earnings
- Net margin-1343.1% as of 2026-08-24
- ROE-1306.7% as of 2026-08-24
- Debt / equity5.03 as of 2026-08-24
- Revenue growth (YoY)+0.4% as of 2026-08-24
- Revenue CAGR (3y)+21.0% SEC XBRL
- Beta2.22 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How OCGN compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OCUGEN INC looks technically
OCUGEN INC (OCGN) is trading 7.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 47 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 49.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 7.9% below its 200-day average, the long-term trend line — a long-term downtrend | -7.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.35 | $1.35 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.51 | $1.51 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.17. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 47 trading days ago — a "death cross", a bearish long-term signal | 47 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.21 to $1.49) — its "stochastic" reading is 64 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 64.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.72 | $2.72 |
|---|---|---|
| From the 52-week high | it is 49.0% below its 52-week high (its highest price of the past year) | -49.0% |
| Above the 52-week low | it is 40.4% above its 52-week low (its lowest price of the past year) | +40.4% |
| Below the 52-week high | it is 49.0% below its highest point of the past year | 49.0% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 47 trading days ago | 47 sessions |
| All-time high | its highest closing price on record is $778.20 (set on 2014-12-03) | $778.20 |
| Given back of the 52-week move | over the past year its closes ranged ($1.01 to $2.48), and it has given back well over two thirds of its rise from last year’s low — 74% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.52 to $1.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.2% |
| From the all-time high | it is 99.8% below its all-time high | -99.8% |
| Nearest price level | it is trading 5.8% below a resistance level at $1.47 — a price it turned at twice since 2025-10-22, most recently on 2026-01-21. Since 2024-08-21 it has 9 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +5.8% |
| All-time low | its lowest closing price on record is $0.17 (set on 2020-06-01) | $0.17 |
| Above the all-time low | it is 717.6% above its all-time low | +717.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0772 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0772 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.17 and $1.46 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.17 – $1.31 – $1.46 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (7.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.55× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Open gap | it gapped 2.0% below the previous close 1 session ago and has not traded back through the level it left behind at 1.48 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
| Gap filled | a 2.7% gap down opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.6 percentage points (the stock gained 6.9% while the market gained 2.3%) | +4.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.1 percentage points (the stock gained 3.0% while the market gained 3.1%) | -0.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.2 percentage points (the stock lost 13.1% while the market gained 11.1%) | -24.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 17.1 percentage points (the stock gained 37.6% while the market gained 20.5%) | +17.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.0% of the share price. | -3.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.65 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | -15.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $1.36 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +2.4% |
Price levels it has turned at before
OCGN last closed at $1.39 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.47 | Resistance | 5.8% above the last close | turned there twice · 2025-10-22 to 2026-01-21 |
| $1.27 | Support | 8.7% below the last close | turned there twice · 2024-09-11 to 2026-05-19 |
| $1.58 | Resistance | 13.7% above the last close | turned there twice · 2025-12-18 to 2026-04-24 |
| $1.17 | Support | 15.8% below the last close | turned there three times · 2025-07-24 to 2026-07-29 |
| $1.13 | Support | 19.1% below the last close | turned there twice · 2024-09-06 to 2024-11-08 |
| $1.69 | Resistance | 21.2% above the last close | turned there twice · 2026-04-07 to 2026-06-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.17.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$12.17 range $8.00 – $22.00; median $10.50
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OCGN
- Consensus EPS estimate-$0.05333 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: regulatory approval of OCU400, OCU410ST, and OCU410 is uncertain; the company must successfully complete Phase 3 trials and obtain FDA/EMA approval, with topline Phase 3 data for OCU400 not expected until Q1 2027.","Funding risk: as an unprofitable, clinical-stage company with negative net margins of -1158.59%, Ocugen requires continuous additional financing to fund ongoing development programs and operations; failure to secure adequate capital could delay or halt programs.","Market adoption and reimbursement risk: even if OCU400, OCU410ST, and OCU410 are approved, there is no guarantee of market acceptance, adequate pricing, reimbursement coverage, or commercial success in competing markets for inherited retinal disease treatments."]
What changed in the latest 10-Q
AI-assisted comparison of OCGN's 10-Q filed 2026-05-08 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'audited financial statements for the year ended December 31, 2025' instead of 2024 (2026-05-08 filing)
- Positive long-term, 3-year Phase 1/2 data for OCU400 announced, showing consistent clinically meaningful approximately 2-line LLVA gain across mutations (2026-05-08)
- 88% (7/8) of evaluable treated subjects showed improvement or preservation versus untreated fellow eyes over 3 years (2026-05-08)
- Approximately 2-line gain (N=8) observed across multiple mutation types at 3 years (2026-05-08)
- OCU400 Phase 3 liMeliGhT enrollment completion announced with N=140 subjects (2026-05-08)
- Rolling BLA submission expected to begin Q3 2026, with completion by Q2 2027 (2026-05-08)
- Topline Phase 3 data expected in Q1 2027, with potential approval in Q4 2027 (2026-05-08)
- Specific timing for OCU410ST BLA submission stated as 'mid-2027' (2026-05-08)
- Strategic goal changed to 'filing three BLAs by 2028' (2026-05-08)
- November 2024 EMA OMPD designation for OCU410ST mentioned with specific indication details (2026-05-08)
- May 2025 FDA RPDD for OCU410ST announced (2026-05-08)
- January 2026 publication of Phase 1 GARDian1 Trial results for OCU410ST (2026-05-08)
- OCU410ST Phase 1 trial showed 54% slower atrophic lesion growth at 12 months (2026-05-08)
- 1-line BCVA gain demonstrated in OCU410ST Phase 1 trial (2026-05-08)
- 100% of evaluable treated eyes showed stabilization or improvement in OCU410ST Phase 1 (2026-05-08)
- 116% slower ellipsoid zone loss in OCU410ST-treated eyes compared to untreated fellow eyes (2026-05-08)
- April 2026 announcement of early completion of OCU410ST Phase 2/3 dosing (N=63 subjects) in less than 9 months (2026-05-08)
- March 2026 positive 12-month topline data from OCU410 Phase 2 ArMaDa trial (2026-05-08)
- 31% reduction in lesion growth in optimal dose (medium) group for OCU410 (p<0.05) (2026-05-08)
- 27% slower rate of ellipsoid zone loss for OCU410 indicating photoreceptor structural preservation (2026-05-08)
- 55% of treated patients demonstrated ≥30% lesion size reduction for OCU410 versus control (2026-05-08)
- Subgroup analysis showing 33% reduction in lesion growth for OCU410 in medium dose with baseline GA lesions ≥5 mm² and ≤17.5 mm² (2026-05-08)
- No OCU410-related serious adverse events observed in Phase 2 trial (2026-05-08)
- Removed:
- Statement that Phase 3 liMeliGhT enrollment was 'actively recruiting' and 'on track to complete enrollment in support of our target BLA and MAA filings in 2026' (2025-11-05)
- Statement about strategic goal of 'filing three BLAs over the next three years' (2025-11-05)
- Statement that OCU410ST BLA would be submitted 'in 2027' with less specificity (2025-11-05)
- Mention that modifier gene therapy platform 'has the potential to address multifactorial retinal diseases including dry age-related macular degeneration (dAMD)' in OCU410ST section (2025-11-05)
- Reference to 'Stargardt disease' terminology variations (2025-11-05)
- Details about OCU200 novel biologic therapy for retinal diseases (2025-11-05)
- Details about regenerative medicine cell therapy platform including NeoCart (2025-11-05)
- Details about inhaled mucosal vaccine platform including OCU500, OCU510, and OCU520 (2025-11-05)
- Details about 2025 Registered Direct Offering (2025-11-05)
- Reworded:
- Reference year changed from 'December 31, 2024' to 'December 31, 2025' in opening paragraph (2026-05-08 vs 2025-11-05)
- Reference changed from '2024 Annual Report' to '2025 Annual Report' (2026-05-08 vs 2025-11-05)
- Reference changed from '2025 Quarterly Reports' to specific reference to 'Risk Factors' section in newer filing (2026-05-08 vs 2025-11-05)
- Ordering of regulatory approvals for OCU410ST rearranged with November 2024 OMPD now preceding May 2025 RPDD announcement (2026-05-08 vs 2025-11-05)
- Changed 'Stargardt disease' to 'ST' abbreviation usage in several places (2026-05-08)
- Reference to CHMP review of 'Stargardt disease' changed to 'ST' in August 2025 announcement (2026-05-08 vs 2025-11-05)
- Notes:
- The newer filing covers the quarter ended March 31, 2026, while the older filing covers the quarter ended September 30, 2025, resulting in expected content differences reflecting clinical trial progression
- The older filing text appears truncated at the end, potentially omitting additional content from the older MD&A section
Risk Factors
- Added:
- Added reference to 'OpCo' (Ocugen OpCo, Inc., the Company's wholly owned subsidiary) in the opening definitional paragraph (filed 2026-05-08)
- Added statement about ability to continue Phase 3 trial for OCU400 without specific reference to 'dosing patients' (filed 2026-05-08)
- Added statement about ability to continue Phase 2/3 pivotal confirmatory trial for OCU410ST without specific reference to 'dosing patients' (filed 2026-05-08)
- Added bullet point regarding estimates and expectations regarding cash, cash reserves and expense levels, future revenues, capital requirements and needs for additional financing, including expected use of proceeds from public offerings, and liquidity sources (filed 2026-05-08)
- Added reference to '2025 Annual Report' filed March 4, 2026 (filed 2026-05-08)
- Removed:
- Removed reference to '2024 Annual Report' filed March 5, 2025 (filed 2025-11-05)
- Removed reference to Quarterly Reports for quarters ended March 31, 2025, June 30, 2025 filed May 09, 2025 and August 4, 2025 (filed 2025-11-05)
- Removed phrase 'the results from our ongoing Phase 1/2 trials' related to OCU400, OCU410 and OCU410ST (filed 2025-11-05)
- Removed phrase 'our ability to continue dosing patients for our Phase 3 trial' (filed 2025-11-05)
- Removed phrase 'our ability to continue dosing patients for our Phase 2/3 pivotal confirmatory trial' (filed 2025-11-05)
- Removed abbreviation expansion for CDMOs in parentheses (filed 2025-11-05)
- Removed abbreviation expansion for GMP in parentheses (filed 2025-11-05)
- Removed reference to '2025 Quarterly Reports' (filed 2025-11-05)
- Removed final sentence fragment regarding trademarks and ® or ™ symbols (filed 2025-11-05)
- Reworded:
- Changed 'the performance of third-parties upon which we depend' to 'the performance of third parties upon which we depend' (removal of hyphen after 'third') (filed 2026-05-08)
- Changed 'defend our intellectual property rights against third-parties' to 'defend our intellectual property rights against third parties' (removal of hyphen after 'third') (filed 2026-05-08)
- Changed reference from 'our 2024 Annual Report and in our 2025 Quarterly Reports, particularly under the section titled "Risk Factors,"' to 'our 2025 Annual Report and in this Quarterly Report on Form 10-Q, particularly under the section titled "Risk Factors,"' (filed 2026-05-08)
- Changed 'the documents we have filed or incorporated by reference as exhibits' to 'the documents we have filed as exhibits' (removal of 'or incorporated by reference') (filed 2026-05-08)
- Notes:
- The newer filing appears to be truncated at the end (cutting off mid-sentence with 'Solely for convenience, t'), while the older filing text also appears truncated but with slightly different content at the end
- Complete Risk Factors section content is not provided in either filing excerpt - only table of contents and forward-looking statements disclosure are shown
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($25830) · 0 sells — 1 buying insider
- Last 180 days1 buy ($25830) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-15. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OCGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding OCGN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 20,303,801
- Reported value $36,749,880
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OCGN had 100,913,607 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OCGN had 29.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 21.55 days to cover at the same settlement.
- Reported short interest (shares) 100,913,607
- Short interest (% of shares outstanding) 29.8%
- Prior settlement (shares) 100,590,405
- Reported change 0.32%
- Days to cover (reported) 21.55
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Spark Therapeutics (SRPT)
- Luxturna (gene therapy for RPE65-mediated inherited retinal disease, approved; parent company vying for expanded use)
- Biogen (BIIB)
- Novartis (NVS)
- Roche / Genentech
- Janssen Pharmaceuticals
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OCGN vs…
OCGN ranks in…
Frequently asked questions
What does OCUGEN INC (OCGN) do?
Ocugen is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and blindness. The company's core platform is a novel modifier gene therapy approach using nuclear hormone receptors (NHRs) to address genetic blindness diseases with a gene-agnostic strategy.
What sector is OCUGEN INC (OCGN) in?
OCUGEN INC (OCGN) is classified in the Health Care sector. Its industry is Gene therapy / inherited retinal disease treatment. It trades on NASDAQ.
Who are OCUGEN INC's (OCGN) competitors?
Notable peers of OCUGEN INC (OCGN) include Spark Therapeutics, Luxturna (gene therapy for RPE65-mediated inherited retinal disease, approved; parent company vying for expanded use), Biogen, Novartis and Roche / Genentech. This peer set is informational only — not financial advice.
Is OCUGEN INC (OCGN) overbought or oversold right now?
OCUGEN INC (OCGN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OCGN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.